Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Achieve Life Sciences Inc (ACHV)

Achieve Life Sciences Inc (ACHV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 264,573
  • Shares Outstanding, K 53,234
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,830 K
  • EBIT $ -52 M
  • EBITDA $ -52 M
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.56

Options Overview Details

View History
  • Implied Volatility 290.81% (+167.77%)
  • Historical Volatility 64.67%
  • IV Percentile 81%
  • IV Rank 30.31%
  • IV High 768.70% on 04/09/25
  • IV Low 82.99% on 07/02/25
  • Expected Move (DTE 9) 0.44 (8.50%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,747
  • Volume Avg (30-Day) 763
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 23,501
  • Open Int (30-Day) 27,224
  • Expected Range 4.76 to 5.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.30
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.22 +23.08%
on 12/17/25
5.30 -1.89%
on 01/07/26
+0.58 (+12.55%)
since 12/05/25
3-Month
3.03 +71.62%
on 10/14/25
5.78 -10.03%
on 10/21/25
+1.88 (+56.63%)
since 10/07/25
52-Week
1.84 +182.61%
on 04/09/25
5.78 -10.03%
on 10/21/25
+1.47 (+39.41%)
since 01/07/25

Most Recent Stories

More News
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

SEATTLE and VANCOUVER, BC , Dec. 17, 2025 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization...

ACHV : 5.20 (+4.21%)
Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 5.20 (+4.21%)
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025...

ACHV : 5.20 (+4.21%)
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully Concluded DSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British...

ACHV : 5.20 (+4.21%)
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 5.20 (+4.21%)
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) --  Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 5.20 (+4.21%)
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National...

ACHV : 5.20 (+4.21%)
Achieve Life Sciences Announces Leadership Change

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Achieve Life...

ACHV : 5.20 (+4.21%)
Achieve Life Sciences Announces Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 5.20 (+4.21%)
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

SEATTLE and VANCOUVER, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 5.20 (+4.21%)

Business Summary

Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc.,...

See More

Key Turning Points

3rd Resistance Point 5.59
2nd Resistance Point 5.45
1st Resistance Point 5.32
Last Price 5.20
1st Support Level 5.05
2nd Support Level 4.91
3rd Support Level 4.78

See More

52-Week High 5.78
Last Price 5.20
Fibonacci 61.8% 4.27
Fibonacci 50% 3.81
Fibonacci 38.2% 3.35
52-Week Low 1.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar